Magnesium sulfate is the most effective, low-cost treatment for preeclampsia/eclampsia, the second leading cause of maternal death in developing countries; yet it is widely underutilized. In this poster, created for the 2013 Saving Lives at Birth DevelopmentXChange, PATH proposed to develop a rectally delivered mucoadhesive gel containing magnesium sulfate. This will increase overall access to and the use of a critical anticonvulsant therapy for women with severe, life-threatening preeclampsia/eclampsia.
Corporate author(s): PATH
Publication date: July 2013
1,368 KB PDF
Hard copies are not available.
Some digital files may be saved at low resolutions to conserve file size. Versions with higher quality may be available; see the contact information below to enquire.
For more information…
Contact: PATH Publications
Mailing address: PATH, PO Box 900922, Seattle, WA 98109 USA